Mir O - Search Results

1

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.

Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, Besse B. Geraud A, et al. Among authors: mir o. Cancers (Basel). 2020 Dec 14;12(12):3758. doi: 10.3390/cancers12123758. Cancers (Basel). 2020. PMID: 33327482 Free PMC article.

2

[Taxane-induced skin toxicity and TNF-alpha].

Mir O, Adam J. Mir O, et al. Presse Med. 2008 Feb;37(2 Pt 1):252-3. doi: 10.1016/j.lpm.2007.09.014. Epub 2008 Jan 11. Presse Med. 2008. PMID: 18191367 French. No abstract available.

3

Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.

Berveiller P, Vinot C, Mir O, Broutin S, Deroussent A, Seck A, Camps S, Paci A, Gil S, Tréluyer JM. Berveiller P, et al. Among authors: mir o. Am J Obstet Gynecol. 2012 Dec;207(6):514.e1-7. doi: 10.1016/j.ajog.2012.10.007. Epub 2012 Oct 8. Am J Obstet Gynecol. 2012. PMID: 23174392

4

Nilotinib versus imatinib for GIST.

Gougis P, Paci A, Coriat R, Urien S, Mir O. Gougis P, et al. Among authors: mir o. Lancet Oncol. 2015 Jul;16(7):e311. doi: 10.1016/S1470-2045(15)00065-0. Lancet Oncol. 2015. PMID: 26149879 No abstract available.

5

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.

Helissey C, Biondani P, Roquet F, Lanoy E, Mir O, Varga A, Massard C, Gazzah A, Ribrag V, Bahleda R, Postel-Vinay S, Angevin E, Deutsch E, Soria JC, Hollebecque A. Helissey C, et al. Among authors: mir o. Int J Cancer. 2016 Feb 15;138(4):875-80. doi: 10.1002/ijc.29849. Epub 2015 Oct 13. Int J Cancer. 2016. PMID: 26370299 Free article.

6

[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].

Jovelet C, Broutin S, Gil S, Mir O, Paci A. Jovelet C, et al. Among authors: mir o. Bull Cancer. 2016 May;103(5):478-83. doi: 10.1016/j.bulcan.2016.02.001. Epub 2016 Mar 8. Bull Cancer. 2016. PMID: 26969425 Review. French.

7

Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series.

Verret B, Honore C, Dumont S, Terrier P, Adam J, Cavalcanti A, Sourrouille I, Klausner G, Ahlenc-Gelas M, Kiavue N, Domitrescu G, El Amarti L, Mir O, Le Cesne A. Verret B, et al. Among authors: mir o. Anticancer Drugs. 2017 Jan;28(1):116-119. doi: 10.1097/CAD.0000000000000435. Anticancer Drugs. 2017. PMID: 27782906

8

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Boissier E, Mir O, Hollebecque A, Izzedine H, Ederhy S, Gazzah A, Bahleda R, Massard C, Macquin-Mavier I, Tournigand C, Spano JP, Soria JC, Rousseau B. Boissier E, et al. Among authors: mir o. Invest New Drugs. 2017 Feb;35(1):79-86. doi: 10.1007/s10637-016-0402-3. Epub 2016 Oct 25. Invest New Drugs. 2017. PMID: 27783256

9

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, Mir O. Loulergue P, et al. Among authors: mir o. Invest New Drugs. 2017 Apr;35(2):247-249. doi: 10.1007/s10637-016-0405-0. Epub 2016 Nov 12. Invest New Drugs. 2017. PMID: 27838867

10

Individualized Pazopanib Dosing-Letter.

Mir O, Broutin S, Perret A, Le Cesne A, Paci A. Mir O, et al. Clin Cancer Res. 2016 Dec 15;22(24):6298. doi: 10.1158/1078-0432.CCR-16-2104. Clin Cancer Res. 2016. PMID: 27980022 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

338 results

Search Page